title: The Cost-Effectiveness of Emergency Hormonal Contraception with Ulipristal Acetate versus Levonorgestrel for Minors in France.
abstract: OBJECTIVE
  To evaluate the cost-effectiveness of ulipristal acetate and levonorgestrel in minors in France, and analyze whether it is worthwhile to provide ulipristal acetate to minors free of charge.
  
  
  METHODS
  The cost-effectiveness of two emergency contraceptive methods was compared based on a decision-analytical model. Pregnancy rates, outcomes of unintended pregnancies, and resource utilization were derived from the literature. Resources and their costs were considered until termination or a few days after delivery. Deterministic and probabilistic sensitivity analyses were performed.
  
  
  RESULTS
  The cost of an unintended pregnancy in a French minor is estimated to be 1,630 € (range 1,330 € - 1,803 €). Almost 4 million € (3.1 € - 13.7 € million) in unintended pregnancy spending in 2010 could have been saved by the use of ulipristal acetate instead of levonorgestrel. The incremental cost of ulipristal acetate compared to levonorgestrel is 3.30 € per intake, or 418 € per pregnancy avoided (intake within 72 hours). In the intake within 24 hours subgroup, ulipristal acetate was found to be more efficacious at a lower cost compared to levonorgestrel.
  
  
  CONCLUSIONS
  Ulipristal acetate dominates levonorgestrel when taken within 24 hours after unprotected intercourse, i.e., it is more effective at a lower cost. When taken within 72 hours, ulipristal acetate is a cost- effective alternative to levonorgestrel, given that the cost of avoiding an additional pregnancy with ulipristal acetate is less than the average cost of these pregnancies. In the light of these findings, it is worthwhile to provide free access to minors.
authors.affiliation: HRA Pharma, Paris, France.
authors.forename: Ramona
authors.initials: R
authors.lastname: Schmid
mesh_terms: D000293:Adolescent; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000191:economics*; D003365:Costs and Cost Analysis; D005260:Female; D005602:France; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000191:economics*; D009649:Norpregnadienes / Q000008:administration & dosage / Q000191:economics*; D011247:Pregnancy; D011275:Pregnancy, Unwanted
chemical_list: D003278:Contraceptives, Oral, Hormonal; D009649:Norpregnadienes; D016912:Levonorgestrel; C555622:ulipristal acetate